This Plain Language Summary of publication article (PLSP) from Future Oncology covers the ongoing TALAPRO-3 study, which is examining the combined use of talazoparib and enzalutamide in treating metastatic castration-sensitive prostate cancer with specific DNA repair gene mutations. The study, which started in May 2021, involves 599 patients across 27 countries.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer’ published in Future Oncology.

Visit Taylor & Francis Online using the link to read the original article